This study evaluated the synergistic effect of curcumin (diferuloylmethane) and hinokitiol (β-thujaplicin), natural product derived phytochemicals, on gefitinib (Iressa) resistant non-small cell lung cancer (NSCLC) cells. Gefitinib, a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR), is widely used for lung cancer treatment. However, gefitinib resistance is easily acquired by NSCLC and followed by the development of progressive disease. Curcumin and hinokitiol are well-known bioactive compounds demonstrating anti-inflammation, anti-bacteria and anticancer effects. However, the effects of co-treatment of curcumin and hinokitiol on cancer cells have not been reported. Here, we postulated, for the first time, the possibility of combination therapy with curcumin and hinokitiol for treatment of gefitinib resistant NSCLC via increment of apoptosis and lysosomal enlargement.
DenisenkoT.V., BudkevichI.N., ZhivotovskyB. (2018) Cell death-based treatment of lung adenocarcinoma. Cell Death & Disease, 9, 117.
2.
HousmanG., BylerS., HeerbothS., LapinskaK., LongacreM., SnyderN., SarkarS. (2014) Drug resistance in cancer: an overview. Cancers, 6, 1769–1792.
3.
WilkenR., VeenaM.S., WangM.B., SrivatsanE.S. (2011) Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Molecular Cancer, 10, 12.
4.
AliB.H., MarrifH., NoureldayemS.A., BakheitA.O., BlundenG. (2006) Some biological properties of curcumin: A review. Natural Product Communications, 1, 509–521.
JacobJ.N., BadyalD.K., BalaS., ToloueM. (2013) Evaluation of the in vivo anti-inflammatory and analgesic and in vitro anti-cancer activities of curcumin and its derivatives. Natural Product Communications, 8, 359–362.
7.
WangW.K., LinS.T., ChangW.W., LiuL.W., LiT.Y.T., KuoC.Y., HsiehJ.L., LeeC.H. (2016) Hinokitiol induces autophagy in murine breast and colorectal cancer cells. Environmental Toxicology, 31, 77–84.
8.
WatanabeK., MatsuuraK., GaoP., HottenbacherL., TokunagaH., NishimuraK., ImazuY., ReissenweberH., WittC.M. (2011) Traditional Japanese Kampo Medicine: clinical research between modernity and traditional medicine-the state of research and methodological suggestions for the future. Evidence-Based Complementary and Alternative Medicine, 2011, 513842.
9.
KuttanR., SudheeranP.C., JosphC.D. (1987) Turmeric and curcumin as topical agents in cancer therapy. Tumori Journal, 73, 29–31.
10.
MatsumuraE., MoritaY., DateT., TsujiboH., YasudaM., OkabeT., IshidaN., InamoriY. (2001) Cytotoxicity of the hinokitiol-related compounds, gamma-thujaplicin and beta-dolabrin. Biological Pharmaceutical Bulletin, 24, 299–302.
11.
TroseljK.G., KujundzicR.N. (2014) Curcumin in combined cancer therapy. Current Pharmaceutical Design, 20, 6682–6696.
12.
ShihY.H., ChangK.W., HsiaS.M., YuC.C., FuhL.J., ChiT.Y., ShiehT.M. (2013) In vitro antimicrobial and anticancer potential of hinokitiol against oral pathogens and oral cancer cell lines. Microbiological Research, 168, 254–262.
13.
BurrisHAIII. (2013) Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemotherapy and Pharmacology, 71, 829–842.
14.
GaoY., ShenJ.K., MilaneL., HornicekF.J., AmijiM.M., DuanZ. (2015) Targeted cancer therapy; nanotechnology approaches for overcoming drug resistance. Current Medicinal Chemistry, 22, 1335–1347.
15.
Maugeri-SaccaM., ViciP., LauroL.D., BarbaM., AmoreoC.A., GalloE., MottoleseM., MariaR.D. (2014) Cancer stem cells: are they responsible for treatment failure?Future Oncology, 10, 2033–2044.
16.
ChenP., LiJ., JiangH.G., LanT., ChenY.C. (2015) Curcumin reverses cisplatin resistance in cisplatin-resistant lung cancer cells by inhibiting FA/BRCA pathway. Tumor Biology, 36, 3591–3599.
17.
BenarbaB., PandiellaA. (2018) Colorectal cancer and medicinal plants: Principle findings from recent studies. Biomedicine & Pharmacotherapy, 107, 408–423.
18.
ParkS.H., KimJ.H., KoE., KimJ.Y., ParkM.J., KimM.J., SeoH., LiS., LeeJ.Y. (2018) Resistance to gefitinib and cross-resistance to irreversible EGFR-TKIs mediated by disruption of the Keap1-Nrf2 pathway in human lung cancer cells. The FASEB Journal, 32, fj201800011R.
19.
MaS., HuangD., ZhaiM., YangL., PengS., ChenC., FengX., WengQ., ZhangB., XuM. (2015) Isolation of a novel bio-peptide from walnut residual protein inducing apoptosis and autophagy on cancer cells. BMC Complementary and Alternative Medicine, 15, 413.
20.
FujikiH., SueokaE., WatanabeT., SuganumaM. (2015) Synergistic enhancement of anticancer effects on numerous human cancer cell lines treated with the combination of EGCG, other green tea catechins, and anticancer compounds. Journal of Cancer Research and Clinical Oncology, 141, 1511–1522.
21.
Kojima-YuasaA., HuangX., Matsui-YuasaI. (2015) Synergistic anticancer activities of natural substances in human hepatocellular carcinoma. Diseases, 3, 260–281.
22.
TiwariR.V., ParajuliP., SylvesterP.W. (2015) Synergistic anticancer effects of combined gamma-tocotrienol and oridonin treatment is associated with the induction of autophagy. Molecular and Cellular Biochemistry, 408, 123–137.
23.
ElmoreS. (2007) Apoptosis: a review of programmed cell death. Toxicologic Pathology, 35, 495–516.
24.
KirkegaardT., JaattelaM. (2009) Lysosomal involvement in cell death and cancer. Biochimica et Biophysica Acta, 1793, 746–754.
25.
FennellyC., AmaravadiR.K. (2017) Lysosomal biology in cancer. Methods in Molecular Biology, 1594, 293–308.
26.
ColomboF., TrombettaE., CetrangoloP., MaggioniM., RaziniP., SantisF.D., TorrenteY., PratiD., TorresaniE., PorrettiL. (2014) Giant lysosomes as a chemotherapy resistance mechanism in hepatocellular carcinoma cells. PLoS One, 9, e114787.
